Sverige - svenska - Läkemedelsverket (Medical Products Agency)

alfasan nederland bv - pimobendan - tuggtablett - 10 mg - pimobendan 10 mg aktiv substans; laktosmonohydrat hjälpämne - hund

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

alfasan nederland bv - pimobendan - tuggtablett - 5 mg - pimobendan 5 mg aktiv substans; laktosmonohydrat hjälpämne - hund

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

alfasan nederland bv - pimobendan - tuggtablett - 15 mg - laktosmonohydrat hjälpämne; pimobendan 15 mg aktiv substans - hund

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

alfasan nederland bv - meloxikam - injektionsvätska, lösning - 20 mg/ml - etanol, vattenfri hjälpämne; meloxikam 20 mg aktiv substans - häst, nöt, svin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

alfasan nederland bv - xylazinhydroklorid - injektionsvätska, lösning - 20 mg/ml - xylazinhydroklorid 23,3 mg aktiv substans - hund, häst, katt, nöt

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

alfasan nederland bv - meloxikam - oral suspension - 15 mg/ml - meloxikam 15 mg aktiv substans; sorbitol hjälpämne; xylitol hjälpämne; glycerol hjälpämne; natriumbensoat hjälpämne - häst

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

alfasan nederland bv - meloxikam - tuggtablett - 0,25 mg - meloxikam 0,25 mg aktiv substans; laktosmonohydrat hjälpämne - katt

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

alfasan nederland bv - detomidinhydroklorid - injektionsvätska, lösning - 10 mg/ml - detomidinhydroklorid 10 mg aktiv substans; metylparahydroxibensoat hjälpämne - häst, nöt

Europeiska unionen - svenska - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - immunsuppressiva - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) är indicerat för behandling av vuxna patienter med tidigare obehandlat multipelt myelom som inte är berättigade till transplantation. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 och 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) är indicerat för behandling av vuxna patienter med tidigare obehandlat multipelt myelom som inte är berättigade till transplantation. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 och 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Europeiska unionen - svenska - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - immunsuppressiva - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) är indicerat för behandling av vuxna patienter med tidigare obehandlat multipelt myelom som inte är berättigade till transplantation. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).